Tremelimumab, Durvalumab, and Belinostat for the Treatment of ARID1A Mutated Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma

• Status: Not yet recruiting
• Trial end date: 2025-11-30

Summary

This phase I trial studies the side effects and best dose of belinostat when given together with tremelimumab and durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Belinostat is a potential anti-cancer drug, known as a histone deacetylase (HDAC) inhibitor, which means that belinostat stops the activity of HDAC enzymes (an enzyme is a protein that in small amounts can speed up a biological reaction). HDAC enzymes play an important role in cell growth and cell death. Giving tremelimumab, durvalumab, and belinostat may improve the body's ability to fight cancer.

• Phase: Phase 1

Details

• Lead Sponsor: University of Utah
• Collaborator: National Cancer Institute (NCI)
• Treatments: Antibodies, Monoclonal; Belinostat; Durvalumab; Immunoglobulin G; Immunoglobulins; Ipilimumab; Tremelimumab